Mary Rezk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mary Rezk has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Anders Jeppsson
Sahlgrenska University Hospital
3 shared publications - Amar Taha
University of Gothenburg
2 shared publications - Florian Ernst Martin Herrmann
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , 405 30 Gothenburg
2 shared publications - Anders Ahlsson
Department of Medical Sciences, Faculty of Medicine and Health, Örebro University , Örebro, SE-70182
1 shared publication - Andreas Martinsson
University of Gothenburg
1 shared publication Christian Hagl
LMU Munich
1 shared publication
Latest Publications
- Open Access
- 9 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (6) , 494-495
Bleeding risk assessment in patients with new-onset atrial fibrillation after coronary surgery (reply)
- 9 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (6) , 494-495
Open AccessBleeding risk assessment in patients with new-onset atrial fibrillation after coronary surgery (reply)
- Open Access
- 7 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (19) , e043026
Outcomes in Early Postoperative Versus Late New‐Onset Atrial Fibrillation After Coronary Artery Bypass Grafting
Background: It is unclear whether new‐onset postoperative atrial fibrillation (POAF) early after coronary artery bypass grafting (CABG) is associated with a similar risk of adverse outcomes as new‐onset atrial fibrillation occurring later after CABG. Methods: All patients treated with CABG in Sweden from 2007 to 2020 were investigated. Individual patient data from SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence‐Based Care in Heart Disease Evaluated According to Recommended Therapies) registry and 3 other prospective national registries were merged. The adjusted incidences of all‐cause mortality, ischemic stroke, any thromboembolism, heart failure hospitalization, and major bleeding within 12 months after debut of POAF (AF occurring before hospital discharge) or Late AF (new‐onset AF occurring between 3 months and 3 years after CABG) were compared by multivariable Poisson regression analysis, adjusted for time‐updated patient characteristics and comorbidities. Results: Out of 35 329 patients, 10 609 (30.0%) developed POAF and 628 (2.5%) developed Late AF. The crude mortality rate was lower in patients with POAF than in patients with Late AF (1.88 [95% CI, 1.63–2.17] versus 9.08 [95% CI, 6.92–11.82] per 100 patient‐years). The adjusted incidence rate ratios for all‐cause mortality (2.91 [95% CI, 2.10–3.95]); ischemic stroke (1.70 [95% CI, 1.15–2.44]); any thromboembolism (1.59 [95% CI, 1.11–2.22]), heart failure hospitalization (1.61 [95% CI, 1.19–2.12]); and major bleeding (1.73 [95% CI, 1.24–2.36]) were higher in patients with Late AF. Conclusions: POAF was associated with a markedly lower risk for morbidity and mortality than late new‐onset AF after CABG. POAF and late new‐onset AF after CABG are 2 different clinical entities of AF that may require different treatment strategies.
- 7 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (19) , e043026
Open AccessOutcomes in Early Postoperative Versus Late New‐Onset Atrial Fibrillation After Coronary Artery Bypass Grafting
Background: It is unclear whether new‐onset postoperative atrial fibrillation (POAF) early after coronary artery bypass grafting (CABG) is associated with a similar risk of adverse outcomes as new‐onset atrial fibrillation occurring later after CABG. Methods: All patients treated with CABG in Sweden from 2007 to 2020 were investigated. Individual patient data from SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence‐Based Care in Heart Disease Evaluated According to Recommended Therapies) registry and 3 other prospective national registries were merged. The adjusted incidences of all‐cause mortality, ischemic stroke, any thromboembolism, heart failure hospitalization, and major bleeding within 12 months after debut of POAF (AF occurring before hospital discharge) or Late AF (new‐onset AF occurring between 3 months and 3 years after CABG) were compared by multivariable Poisson regression analysis, adjusted for time‐updated patient characteristics and comorbidities. Results: Out of 35 329 patients, 10 609 (30.0%) developed POAF and 628 (2.5%) developed Late AF. The crude mortality rate was lower in patients with POAF than in patients with Late AF (1.88 [95% CI, 1.63–2.17] versus 9.08 [95% CI, 6.92–11.82] per 100 patient‐years). The adjusted incidence rate ratios for all‐cause mortality (2.91 [95% CI, 2.10–3.95]); ischemic stroke (1.70 [95% CI, 1.15–2.44]); any thromboembolism (1.59 [95% CI, 1.11–2.22]), heart failure hospitalization (1.61 [95% CI, 1.19–2.12]); and major bleeding (1.73 [95% CI, 1.24–2.36]) were higher in patients with Late AF. Conclusions: POAF was associated with a markedly lower risk for morbidity and mortality than late new‐onset AF after CABG. POAF and late new‐onset AF after CABG are 2 different clinical entities of AF that may require different treatment strategies.
- Open Access
- 17 May 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (10) , e024703
Stroke Risk Stratification in Patients With Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting
Background: The CHA 2 DS 2 ‐VASc (congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke or TIA [transient ischemic attack], vascular disease, age 65 to 74 years, sex category female; 2 indicates 2 points, otherwise 1 point) scoring system is recommended to guide decisions on oral anticoagulation therapy for stroke prevention in patients with nonsurgery atrial fibrillation. A score ≥1 in men and ≥2 in women, corresponding to an annual stroke risk exceeding 1%, warrants long‐term oral anticoagulation provided the bleeding risk is acceptable. However, in patients with new‐onset postoperative atrial fibrillation, the optimal risk stratification method is unknown. The aim of this study was therefore to evaluate the CHA 2 DS 2 ‐VASc scoring system for estimating the 1‐year ischemic stroke risk in patients with new‐onset postoperative atrial fibrillation after coronary artery bypass grafting. Methods and Results: All patients with new‐onset postoperative atrial fibrillation and without oral anticoagulation after first‐time isolated coronary artery bypass grafting performed in Sweden during 2007 to 2017 were eligible for this registry‐based observational cohort study. The 1‐year ischemic stroke rate at each step of the CHA 2 DS 2 ‐VASc score was estimated using a Kaplan‐Meier estimator. Of the 6368 patients included (mean age, 69.9 years; 81% men), >97% were treated with antiplatelet drugs. There were 147 ischemic strokes during the first year of follow‐up. The ischemic stroke rate at 1 year was 0.3%, 0.7%, and 1.5% in patients with CHA 2 DS 2 ‐VASc scores of 1, 2, and 3, respectively, and ≥2.3% in patients with a score ≥4. A sensitivity analysis, with the inclusion of patients on anticoagulants, was performed and supported the primary results. Conclusions: Patients with new‐onset atrial fibrillation after coronary artery bypass grafting and a CHA 2 DS 2 ‐VASc score <3 have such a low 1‐year risk for ischemic stroke that oral anticoagulation therapy should probably be avoided.
- 17 May 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (10) , e024703
Open AccessStroke Risk Stratification in Patients With Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting
Background: The CHA 2 DS 2 ‐VASc (congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke or TIA [transient ischemic attack], vascular disease, age 65 to 74 years, sex category female; 2 indicates 2 points, otherwise 1 point) scoring system is recommended to guide decisions on oral anticoagulation therapy for stroke prevention in patients with nonsurgery atrial fibrillation. A score ≥1 in men and ≥2 in women, corresponding to an annual stroke risk exceeding 1%, warrants long‐term oral anticoagulation provided the bleeding risk is acceptable. However, in patients with new‐onset postoperative atrial fibrillation, the optimal risk stratification method is unknown. The aim of this study was therefore to evaluate the CHA 2 DS 2 ‐VASc scoring system for estimating the 1‐year ischemic stroke risk in patients with new‐onset postoperative atrial fibrillation after coronary artery bypass grafting. Methods and Results: All patients with new‐onset postoperative atrial fibrillation and without oral anticoagulation after first‐time isolated coronary artery bypass grafting performed in Sweden during 2007 to 2017 were eligible for this registry‐based observational cohort study. The 1‐year ischemic stroke rate at each step of the CHA 2 DS 2 ‐VASc score was estimated using a Kaplan‐Meier estimator. Of the 6368 patients included (mean age, 69.9 years; 81% men), >97% were treated with antiplatelet drugs. There were 147 ischemic strokes during the first year of follow‐up. The ischemic stroke rate at 1 year was 0.3%, 0.7%, and 1.5% in patients with CHA 2 DS 2 ‐VASc scores of 1, 2, and 3, respectively, and ≥2.3% in patients with a score ≥4. A sensitivity analysis, with the inclusion of patients on anticoagulants, was performed and supported the primary results. Conclusions: Patients with new‐onset atrial fibrillation after coronary artery bypass grafting and a CHA 2 DS 2 ‐VASc score <3 have such a low 1‐year risk for ischemic stroke that oral anticoagulation therapy should probably be avoided.